COMMUNIQUÉS West-GlobeNewswire

Profound Medical Reports Second Quarter 2026 Financial Results
06/08/2026
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and [...]
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
06/08/2026
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported [...]
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
06/08/2026
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in [...]
Globus Medical Reports Second Quarter 2026 Results
06/08/2026
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second [...]
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
06/08/2026
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition [...]
Flyte Achieves Record Revenues in July
06/08/2026
July 2026 Revenue Increased 102% sequential July Over June to Approximately $640,000 Retail Platform, Strategic Partnerships and Influencer Marketing Fuel Accelerating Growth FORT MILL, S.C., Aug. 06, 2026 (GLOBE [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2026
06/08/2026
Lasmé-cel: phase 2 pivotale dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Lasmé-cel a reçu le statut RMAT de la FDA Résultats complets de phase 1 pour lasmé-cel présentés au congrès annuel de l’EHA 2026 [...]
Cellectis Reports Financial Results for the Second Quarter 2026
06/08/2026
Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected in [...]
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
06/08/2026
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
06/08/2026
Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma Silver Spring, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev ( [...]
Sanuwave Announces Q2 FY2026 Financial Results
06/08/2026
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 [...]
VitalHub Reports Second Quarter 2026 Results
06/08/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 28% YoY to $101.5 million Total Revenue up 33% YoY to $31.7 million Adjusted EBITDA⁽¹⁾ up 29% YoY to $8.2 million TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
VitalHub Announces Normal Course Issuer Bid
06/08/2026
TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that the Toronto Stock Exchange (the "Exchange") has accepted a notice filed by VitalHub of [...]
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
06/08/2026
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 [...]
BioStem Technologies Announces Nasdaq Uplisting
06/08/2026
Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the [...]
Biogen Completes Acquisition of RayThera Inc.
07/08/2026
Lead program now in Phase 1 development CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology [...]
Tango Therapeutics Announces Executive Chair Transition
07/08/2026
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today [...]
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
06/08/2026
Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy PHOENIX, Aug. [...]
Kymanox Launches AI-Enabled Quality and Regulatory Capabilities for Life Sciences Organizations
06/08/2026
Built on a foundation of responsible artificial intelligence (AI) use with expert-verified deliverables, Kymanox can now apply AI to Quality Management System (QMS) development, batch release report review, and human [...]

Pages